Skip to main content
    C

    Cytokinetics Inc (CYTK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $53.17
    -2.96 (-5.27%)

    Market Cap: $7.82B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cytokinetics Inc (CYTK) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Cytokinetics (CYTK) to earn -$5.76 per share in the fiscal year ending Dec 31, 2026, on revenue of $164.56M. Of 22 analysts, 20 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 8 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 22 ratings average 1.77, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 91% of the ratings.

    RatingAnalystsShare
    Strong Buy731.8%
    Buy1359.1%
    Hold29.1%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    22

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 169.3%.

    Fiscal year ending Dec 31, 2026
    -$5.76
    EPS consensus, revenue $164.56M
    Fiscal year ending Dec 31, 2027
    -$4.23
    EPS consensus, revenue $443.13M
    Next report
    Feb 22, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$5.76-$6.27 to -$4.6417$164.56M$151.50M to $223.66M18
    Dec 31, 2027-$4.23-$5.71 to -$2.8917$443.13M$316.80M to $594.89M20

    Quarterly Estimates

    The EPS consensus rises from -$1.44 for the quarter ending Dec 31, 2026 to -$1.28 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.44-$1.58 to -$0.9824$66.72M$51.92M to $86.57M22
    Mar 31, 2027-$1.28-$1.55 to -$0.736$75.29M$56.44M to $95.40M6

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 20 upward and 4 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202682
    Fiscal year ending Dec 31, 202792
    Quarter ending Mar 31, 202730

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$5.97.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$5.76-$5.88-$5.94-$5.94-$5.97N/A
    Fiscal year ending Dec 31, 2027-$4.23-$4.40-$4.44-$4.45-$4.43N/A
    Quarter ending Mar 31, 2027-$1.28-$1.32-$1.34-$1.34-$1.28N/A

    Frequently Asked Questions About CYTK

    What is the CYTK stock forecast?

    Consensus analyst estimates put Cytokinetics's EPS at -$5.76 for the fiscal year ending Dec 31, 2026, on revenue of $164.56M. The consensus rating from 22 analysts is Buy.

    How do analysts rate CYTK stock?

    Of 22 analysts covering Cytokinetics, 7 rate it Strong Buy, 13 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from CYTK next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$5.76, with estimates from -$6.27 to -$4.64 from 17 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.23, with estimates from -$5.71 to -$2.89 from 17 analysts.

    What revenue do analysts expect from Cytokinetics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $164.56M, with estimates from $151.50M to $223.66M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $443.13M, with estimates from $316.80M to $594.89M.

    How many analysts cover CYTK?

    22 analysts rate Cytokinetics stock, and 17 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.